Integral Diagnostics' Merger Could Deliver Revenue Synergies -- Market Talk

Dow Jones

2024/12/17

0335 GMT - Integral Diagnostics' merger with Capitol Health could offer investors even more upside to that already included in Macquarie analysts' bullish view of the stock. The analysts tell clients in a note that they see significant EPS accretion from the imaging providers' merger, which last week was approved by an Australian court. They see revenue growth supported by indexation, mix shift and volume growth, with earnings margins expanding due to cost synergies. Yet the companies haven't estimated any revenue synergies, which the Macquarie analysts reckon could emerge, including from the improved use of specialists across clinics. Macquarie raises its target price 21% to A$3.50 and maintains an outperform rating. Shares are down 1.3% at A$2.94. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

December 16, 2024 22:35 ET (03:35 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492605744"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492605744\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492605744?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 11:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492605744","market":"sh","top_or_hot":-1,"title":"Integral Diagnostics' Merger Could Deliver Revenue Synergies -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0335 GMT - Integral Diagnostics' merger with Capitol Health could offer investors even more upside to that already included in <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> analysts' bullish view of the stock. The analysts tell clients in a note that they see significant EPS accretion from the imaging providers' merger, which last week was approved by an Australian court. They see revenue growth supported by indexation, mix shift and volume growth, with earnings margins expanding due to cost synergies. Yet the companies haven't estimated any revenue synergies, which the Macquarie analysts reckon could emerge, including from the improved use of specialists across clinics. Macquarie raises its target price 21% to A$3.50 and maintains an outperform rating. Shares are down 1.3% at A$2.94. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2024 22:35 ET (03:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Integral Diagnostics' Merger Could Deliver Revenue Synergies -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntegral Diagnostics' Merger Could Deliver Revenue Synergies -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-17 11:35</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0335 GMT - Integral Diagnostics' merger with Capitol Health could offer investors even more upside to that already included in <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> analysts' bullish view of the stock. The analysts tell clients in a note that they see significant EPS accretion from the imaging providers' merger, which last week was approved by an Australian court. They see revenue growth supported by indexation, mix shift and volume growth, with earnings margins expanding due to cost synergies. Yet the companies haven't estimated any revenue synergies, which the Macquarie analysts reckon could emerge, including from the improved use of specialists across clinics. Macquarie raises its target price 21% to A$3.50 and maintains an outperform rating. Shares are down 1.3% at A$2.94. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2024 22:35 ET (03:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAJ.AU","symbol_name":"CAPITOL HEALTH LIMITED","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492605744","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492605744","pubTimestamp":1734406500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0335 GMT - Integral Diagnostics' merger with Capitol Health could offer investors even more upside to that already included in Macquarie analysts' bullish view of the stock. The analysts tell clients in a note that they see significant EPS accretion from the imaging providers' merger, which last week was approved by an Australian court. They see revenue growth supported by indexation, mix shift and volume growth, with earnings margins expanding due to cost synergies. Yet the companies haven't estimated any revenue synergies, which the Macquarie analysts reckon could emerge, including from the improved use of specialists across clinics. Macquarie raises its target price 21% to A$3.50 and maintains an outperform rating. Shares are down 1.3% at A$2.94. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CAJ.AU":"CAPITOL HEALTH LIMITED","IDX.AU":"INTEGRAL DIAGNOSTICS LTD","INTEU":"Integral Acquisition Corporation 1"},"translate_title":"Integral Diagnostics的合并可能会带来收入协同效应——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INTEU":1,"IDX.AU":0.9,"CAJ.AU":0.9},"content_text":"0335 GMT - Integral Diagnostics' merger with Capitol Health could offer investors even more upside to that already included in Macquarie analysts' bullish view of the stock. The analysts tell clients in a note that they see significant EPS accretion from the imaging providers' merger, which last week was approved by an Australian court. They see revenue growth supported by indexation, mix shift and volume growth, with earnings margins expanding due to cost synergies. Yet the companies haven't estimated any revenue synergies, which the Macquarie analysts reckon could emerge, including from the improved use of specialists across clinics. Macquarie raises its target price 21% to A$3.50 and maintains an outperform rating. Shares are down 1.3% at A$2.94. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2024 22:35 ET (03:35 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}